With a market capitalization of $160.5 billion, Intuitive Surgical, Inc. (ISRG) develops and markets advanced medical technologies that enable physicians to perform minimally invasive procedures, including its flagship da Vinci Surgical System and Ion endoluminal platform. It also provides integrated instruments, support services and digital solutions to improve surgical outcomes and hospital performance worldwide.
The Sunnyvale, California-based company is expected to soon announce its results for the first fiscal quarter of 2026. Ahead of this event, analysts forecast that Intuitive Surgical will report EPS of $1.63, up 15.6% from $1.41 in the prior-year quarter. It has surpassed Wall Street earnings estimates over the past four quarters.
For fiscal 2026, analysts predict that the medical device maker will post EPS of $8.25, up 14.3% from $7.22 in fiscal 2025. Additionally, EPS is projected to grow 15.2% year-over-year to $9.50 in fiscal 2027.
Intuitive Surgical shares have risen marginally over the past 52 weeks, lagging the S&P 500 Index ($SPX)’s nearly 22% gain and the State Street Health Care Select Sector SPDR ETF’s (XLV) 8.3% return over the same period.
Intuitive Surgical shares fell marginally after its fourth-quarter 2025 results on Jan. 22, as the company projected slower da Vinci procedure growth in 2026, from 13% to 15% compared to 18% in 2025, indicating a moderation in demand. Investor sentiment was further impacted by expected pressure on margins, with adjusted gross margins guided to 67%-68% (up from 67.6% in 2025), including an estimated ~1.2% tariff impact on revenue. Additionally, concerns were raised about further operating expense growth of 11% to 15% in 2026 and a decline in Ion system placements.
The analyst consensus view on ISRG stock is cautiously optimistic, with an overall rating of “Moderate Buy.” Among the 30 analysts covering the stock, 19 suggest a “strong buy”, two give a “moderate buy”, eight recommend a “hold” and one has a “strong sell”. The average analyst price target for Intuitive Surgical is $619.85, indicating a potential upside of 37.1% from current levels.
As of the date of publication, Sohini Mondal had no (directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article are for informational purposes only. This article was originally published on Barchart.com